Premium Nahrungsergänzungsmittel | artgerecht

Bone Turnover Markers – Meaning and Clinical Use

Bone turnover markers are laboratory values that measure the formation and resorption of bone tissue, used in the diagnosis and treatment monitoring of bone diseases.

Regular tips about health Regular tips about health

Things worth knowing about "Bone Turnover Markers"

Bone turnover markers are laboratory values that measure the formation and resorption of bone tissue, used in the diagnosis and treatment monitoring of bone diseases.

What Are Bone Turnover Markers?

Bone turnover markers (BTMs) are biochemical parameters measured in blood or urine that reflect the activity of bone metabolism. Bone is not a static tissue -- it is continuously being formed and resorbed throughout life in a process known as bone remodeling. Bone turnover markers provide a dynamic snapshot of this process, helping clinicians detect bone diseases early, monitor treatment response, and assess fracture risk.

Bone Formation and Bone Resorption Markers

Bone turnover markers are divided into two main categories:

Markers of Bone Formation

These markers are produced by osteoblasts (bone-forming cells) and released into the bloodstream, reflecting the rate of new bone synthesis:

Osteocalcin (OC): A protein produced exclusively by osteoblasts, considered a sensitive indicator of bone formation activity.
Bone-specific alkaline phosphatase (BSAP): An enzyme that plays a key role in the mineralization of bone tissue.
Procollagen type I propeptides (PINP, PICP): Cleavage products generated during the synthesis of type I collagen, the main structural protein of bone. P1NP is the reference marker for bone formation recommended by the IOF (International Osteoporosis Foundation).

Markers of Bone Resorption

These markers are released when osteoclasts (bone-resorbing cells) break down bone tissue:

Beta-CrossLaps (Beta-CTX): Degradation products of type I collagen released during bone resorption. Beta-CTX is the IOF-recommended reference marker for bone resorption.
Deoxypyridinoline (DPD) and Pyridinoline (PYD): Collagen cross-link molecules detectable in urine.
N-telopeptides (NTX) and C-telopeptides (CTX): Breakdown products of type I collagen measurable in blood and urine.
Tartrate-resistant acid phosphatase 5b (TRAP 5b): An osteoclast-specific enzyme indicating the activity of bone-resorbing cells.

When Are Bone Turnover Markers Used?

Bone turnover markers are measured in a variety of clinical situations:

Diagnosis and monitoring of osteoporosis
Treatment monitoring during antiresorptive therapy (e.g., bisphosphonates, denosumab) or osteoanabolic therapy (e.g., teriparatide)
Assessment of Paget's disease of bone (a condition characterized by excessive localized bone remodeling)
Monitoring of bone metastases in oncology patients
Evaluation of hyperparathyroidism, hyperthyroidism, or renal disease affecting bone metabolism
Fracture risk assessment

How Is the Measurement Performed?

Most bone turnover markers are measured from a simple blood sample (serum or plasma); some are measured in urine (e.g., DPD, NTX). Because values are subject to circadian fluctuations, blood collection is recommended in the morning under fasting conditions to ensure comparable results. Physical activity, diet, and immobilization can also influence the measured values.

Interpretation of Results

The interpretation of bone turnover markers always requires clinical context. Elevated resorption markers may indicate increased bone breakdown, while elevated formation markers signal heightened bone synthesis. Ideally, formation and resorption are balanced. An imbalance favoring resorption is characteristic of osteoporosis or bone metastases. Reference ranges vary depending on the laboratory, as well as the age and sex of the patient.

Clinical Relevance and Limitations

Bone turnover markers are not standalone diagnostic tools -- they complement imaging techniques such as DXA bone density measurement and other clinical findings. Their greatest strength lies in treatment monitoring: as early as 3 to 6 months after initiating therapy, markers can indicate whether a treatment is effective -- far earlier than a repeat bone density scan. Limitations include biological variability, pre-analytical influencing factors, and incomplete standardization across laboratories.

References

Vasikaran S. et al. - Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis International, 2011; 22(2): 391-420.
Eastell R. et al. - Bone Turnover Markers in Osteoporosis and Osteoporosis Treatment. Journal of Bone and Mineral Research, 2021; 36(2): 222-235.
World Health Organization (WHO) - Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva, 1994.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.